Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402309 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
A Phase 2 study of Sjögren-Larsson Syndrome, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT02402309: Completed Phase 2 study of Sjögren-Larsson Syndrome, sponsored by Aldeyra Therapeutics.
NCT02402309 is a Phase 2 study of Sjögren-Larsson Syndrome that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02402309, a Phase 2 study of Sjögren-Larsson Syndrome, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to Sjögren- Larsson Syndrome (SLS). NS2 is expected to trap fatty aldehydes that are pathogenic in SLS patients, and thereby diminish the lipid-aldehyde adduct formation that likely results in ichthyosis associated with SLS, and potentially reduce the mild dermal inflammation characteristic of SLS.
Conditions Studied
Interventions
- DRUG Active topical NS2 1% dermatologic cream
- DRUG Vehicle placebo 0.0% NS2 dermatologic cream
Study Locations (3)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Penn State Hershey Medical Center - Department of Dermatology - Hershey
Virginia
- Pediatric and General Dermatology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT02402309 record still lists
NCT02402309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Sjögren-Larsson Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Active topical NS2 1% dermatologic cream is the first listed.
NCT02402309 reports a single indexed study location in Nebraska, Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT02402309 about?
NCT02402309 is a clinical study titled "A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)". This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to Sjögren- Larsso...
What is the current status of trial NCT02402309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2016-06.
What conditions does trial NCT02402309 study?
This clinical trial studies the following conditions: Sjögren-Larsson Syndrome.
What interventions are being tested in trial NCT02402309?
The interventions under investigation include: Active topical NS2 1% dermatologic cream (DRUG), Vehicle placebo 0.0% NS2 dermatologic cream (DRUG).
Who is sponsoring clinical trial NCT02402309?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02402309 being conducted?
This trial has 3 study locations across Nebraska, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02402309's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia